Zentalis Pharmaceuticals, Inc.
ZNTLHealthcare|Biotechnology|US
$1.72
+0.01 (+0.58%)
Tangible Book / Share
$2.04
Cash / Share
$2.49
Clinical Trials (16)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07546500 A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression | Ovarian Cancer | P3 | Recruiting | 420 | RCT, Open-label | Investigator's choice of Chemotherapy, Azenosertib |
| NCT05128825 A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | P2 | Recruiting | 310 | RCT, Open-label | azenosertib |
| NCT06369155 Azenosertib in Uterine Serous Carcinoma: Biomarker Study | Uterine Serous Carcinoma, Uterine Carcinoma | P2 | Recruiting | 25 | Open-label | Azenosertib |
| NCT04516447 A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer | Solid Tumor, Epithelial Ovarian Cancer | P1 | Recruiting | 172 | Open-label | Azenosertib, Carboplatin, Pegylated liposomal doxorubicin, Paclitaxel, Gemcitabine, Bevacizumab |
| NCT06015659 ZN-c3 + Gemcitabine in Pancreatic Cancer | Advanced Pancreatic Adenocarcinoma, Pancreatic Cancer | P2 | Terminated | 12 | Open-label | Zentalis, Gemzar |
| NCT05198804 A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer | Ovarian Cancer, Platinum-resistant Ovarian Cancer | P1P2 | Completed | 117 | Open-label | Azenosertib, Niraparib |
| NCT04814108 A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma | Uterine Serous Carcinoma | P2 | Completed | 92 | Open-label | Azenosertib |
| NCT05199337 Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis | Amyloidosis, AL Amyloidosis | P1P2 | Completed | 18 | Open-label | ZN-d5 |
| NCT05682170 Study of the ZN-d5 and ZN-c3 in Subjects With Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia (AML) | P1P2 | Terminated | 40 | Open-label | ZN-d5 ZN-c3, ZN-c3 |
| NCT04833582 A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma | Osteosarcoma | P1 | Completed | 31 | Open-label | Azenosertib, Gemcitabine |
| NCT04500587 Phase 1 First in Human Study of ZN-d5 as a Single Agent | Acute Myeloid Leukemia, Non Hodgkin Lymphoma | P1 | Completed | 39 | Open-label | ZN-d5 |
| NCT04854174 A Food Effect Study of ZN-d5 in Healthy Female Volunteers | Healthy Volunteers | P1 | Completed | 16 | Open-label | ZN-d5 |
| NCT05743036 ZN-c3 in Adult Participants With Metastatic Colorectal Cancer | Metastatic Colorectal Cancer | P1 | Terminated | 44 | RCT, Open-label | ZN-c3, Encorafenib, Cetuximab |
| NCT04158336 A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors | Solid Tumor | P1 | Completed | 274 | RCT, Open-label | Azenosertib |
| NCT05431582 Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors | Tumors, Ovarian Cancer | P1 | Withdrawn | — | Open-label | ZN-c3, Bevacizumab, Pembrolizumab |
| NCT06351332 ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC | Breast Cancer, Breast Cancer Female | P1 | Terminated | 7 | Open-label | Azenosertib, Carboplatin, Pembrolizumab |